Clinical Trial: A Study of DCC-3014 to Evaluate the Efficacy, Safety, and Pharmacokinetics in Subjects With TGCT

U.S., Sept. 23 -- ClinicalTrials.gov registry received information related to the study (NCT07832747) titled 'A Study of DCC-3014 to Evaluate the Efficacy, Safety, and Pharmacokinetics in Subjects With TGCT' on Sept. 08.

Brief Summary: To evaluate the efficacy, safety, and pharmacokinetics of DCC-3014 in subjects with Tenosynovial Giant Cell Tumor

Study Start Date: Oct. 31

Study Type: INTERVENTIONAL

Condition: Tenosynovial Giant Cell Tumor

Intervention: DRUG: DCC-3014

DCC-3014 will be orally administered at a dose of 30 mg twice weekly.

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Ono Pharmaceutical Co., Ltd.

Disclaimer: Curated by HT Syndication....